BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:STANDARD
TZNAME:GMT
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
DTSTART:19701025T020000
RRULE:FREQ=YEARLY;BYMONTH=10;BYDAY=-1SU
END:STANDARD
BEGIN:DAYLIGHT
TZNAME:BST
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
DTSTART:19700329T010000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=-1SU
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
UID:6a18a8212f89a
DTSTAMP:20260528T204001Z
DTSTART;TZID=Europe/London:20230517T140000
DTEND;TZID=Europe/London:20230517T150000
TZID:Europe/London
SUMMARY:School of Chemistry Colloquium: Dr Irelenia Nobeli (Birkbeck, University of London)
DESCRIPTION:School of Chemistry Colloquium open to final year project students, MSc students, PhD students, post-doctoral researchers and academic staff.      Autism is the most prevalent neurodevelopmental condition, characterised by a great diversity in phenotypes and a lack of a clear molecular mechanism that could explain them. A number of biological processes have been implicated in the aetiology and pathology of autism, ranging from genetic mutations to environmental factors, highlighting the complexity of this condition. Here, I present first, a brief summary of some of our current knowledge of the molecular basis of autism and then focus on our own computational analysis of omics datasets. I will show evidence from transcriptomic studies of post-mortem brain samples that a fundamental process of regulating gene expression in eukaryotes, the decision of where a transcript will terminate, is dysregulated in the autistic brain. I will then present further evidence of changes to gene expression in the autistic brain, as a result of dysregulated selection of both the start and ends of transcripts using specialized sequencing. Finally, I will show that both changes in the efficiency of translation observed in the autistic brain samples and their selective reversal by rapamycin are recapitulated in an in vitro model of Tuberous Sclerosis Complex, a multi-system disorder caused by known genetic mutations that is often accompanied by autistic traits. This observation opens the possibility of using this model to test new therapeutics for severe forms of autism.    Dr Irelenia Nobeli (Birkbeck, University of London) https://events.st-andrews.ac.uk/events/school-of-chemistry-colloquium-dr-irelenia-nobeli-birkbeck-university-of-london/
LOCATION:Purdie Building
URL:https://events.st-andrews.ac.uk/events/school-of-chemistry-colloquium-dr-irelenia-nobeli-birkbeck-university-of-london/
End:VEVENT
End:VCALENDAR